Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
58.6M
-
Shares change
-
-1.13M
-
Total reported value, excl. options
-
$2.77B
-
Value change
-
-$36.6M
-
Put/Call ratio
-
0.82
-
Number of buys
-
57
-
Number of sells
-
-78
-
Price
-
$47.20
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q2 2025
174 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q2 2025.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.6M shares
of 63.5M outstanding shares and own 92.28% of the company stock.
Largest 10 shareholders include BVF INC/IL (19.8M shares), Cormorant Asset Management, LP (8.49M shares), FMR LLC (5.73M shares), Avoro Capital Advisors LLC (4.15M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.61M shares), CITADEL ADVISORS LLC (1.67M shares), GOLDMAN SACHS GROUP INC (1.28M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (1.26M shares), FEDERATED HERMES, INC. (1.25M shares), and ALLIANCEBERNSTEIN L.P. (1.14M shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.